Article by

Katewinslet

Introduction

Acute myeloid leukemia (AML) is a tumor of blood myeloid cells, which are characterized by the unlimited growth of white blood cells. Cells accumulate in the bone marrow, where they disrupt the normal production of blood cells. AML is a relatively rare form of cancer and accounts for only about 1% of cancer deaths in the United States. At the same time increases the most common acute leukemia affecting adults, and the incidence with age, so the incidence is expected to rise dramatically with age.

symptoms of AML include fatigue, shortness of breath, easy bruising and bleeding and increased risk of infection. All these symptoms are caused by abnormal myeloid cells replace normal bone marrow. This leads to the reduction produced by the bone marrow cells, including red blood cells, platelets and normal white blood cells.

the initial diagnosis of AML is usually made of an abnormal blood count. The most common findings are leukocytosis, increased white blood cell count but abnormal white blood cells are also seen. AML may also decrease platelet and red blood cells. The final diagnosis of AML requires a bone marrow biopsy to distinguish other types of leukemia and AML subtype classification. According to WHO criteria commonly used, indicating the diagnosis of AML was established more than 20% myeloblasts in the blood and / or bone marrow. There are several subtypes of AML with different assumptions. Five-year survival ranges from 15-70% and recurrence in the range 33-78%, depending on the subtype.

PROSNOSTIC SPECIFICATIONS

The most important prognostic factor in AML with specific cytogenetic abnormality is related to the disease. Some changes are associated with very good results, such as t (15:17) translocation, while others are associated with poor prognosis and high risk of relapse after treatment. Approximately 50% of AML patients have “normal” cytogenetics, and should fall into the medium risk category.

Other genetic factors play a role in the AML estimate. Internal tandem duplication of the FMS-like tyrosine kinase 3 (FLT3) shows poor forecasting of AML. Although the clinical significance of FLT3 remains unclear, it may be useful in determining the most effective treatment.

HEALTH

AML is an aggressive acute leukemia, which develops rapidly and is usually fatal within weeks or months if left untreated. Initial treatment with chemotherapy for AML has two phases. The first phase is induction. Objective of this phase, a complete remission with chemotherapy, in which abnormal white blood cells are identified. The second phase of consolidation, which aims to completely eliminate undetectable residual disease and thus cure the patient. Some patients may be eligible for haematopoietic stem cell transplantation to restore bone marrow function after a relapse, or whether they are especially high in sub-type.

FLT3 inhibitors

AML is still one of the difficult to treat haematological malignancies who relapse after treatment is high and often poor results. High frequency of activating FLT3 mutations associated with poor prognosis in these patients has led researchers to explore FLT3-based therapies. High-throughput screening has identified potential FLT3 tyrosine kinase inhibitor known Quizartinib (AC220).

Phase II clinical trials are underway to determine the effects of quizartinib in the treatment of AML. Quizartinib tested both individually and in combination with other therapeutic treatment of refractory AML. Preliminary analysis of survey data has shown positive results and will likely continue to develop drugs in phase III trials soon.

Summary

Acute myeloid leukemia (AML) is a somewhat rare hematologic malignancy growing incidence of the U.S. population ages. There are several sub-groups, which can be differentiated diagnosis is based on cytogenetics. Prognosis is highly dependent on the specific subtype identified. AML is an aggressive disease that is fatal within months if not treated. But it’s still very difficult to treat and prone to relapse. Activation mutations of FLT3 tyrosine kinase is associated with a poor forecast of AML. For this reason, quizartinib, FLT3 tyrosine kinase inhibitor currently being studied for the treatment of AML.

LINKS

1 Vardiman JW, Harris NL, Brown and RD (2002). “The World Health Organization (WHO) classification of myeloid neoplasms.” Blood 100 (7): 2292 to 302.2. Le Beau M, Albain K, Larson R, Vardiman J, Davis E, Blough R, Golomb H, Rowley J (1986). “Clinical and cytogenetic correlations of 63 patients with myelodysplastic syndromes and acute nonlymphocytic leukemia. Further evidence of characteristic abnormalities of chromosomes 5 and 7″. J Clin Oncol 4 (3). 325 to 45.3 Taylor GM, Birch JM (1996), “the genetic basis of human leukemia,” Henderson ES, Lister TA, Greaves MF Leukemia (6th ed.) Philadelphia :….. Saunders, p. 210.4 Bishop J (1997) ‘Treatment of adult acute myeloid leukemia .. ” Semin Oncol 24 (1): .. 57 to 69.5 Estey E (2001). “Prognostic factors in acute myeloid leukemia,” Leukemia 15 (4). 670 to 2.6 Schnittger S, Schoch C, Dugas M,. Kern W, Staib P, Wuchter C, Löffler H, Sauerland C, Serve H, Buchner T, Haferlach T, Hiddemann W (2002), “Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia. Correlation cytogenetics, FAB subtype, and learn to forecast and utility AMLCG marker for the detection of minimal residual disease, “Blood 100 (1): 59 to 66.7 Chao, Qi, Sprankle, G. Kelly, Grotzfeld, Robert M., Lai, Andiliy .. G., Carter, Todd A., Velasco, Anne Marie, Gunawardane, Ruwanthi N., Cramer, Merryl D., Gardner, Michael F., James Joyce, Zarrinkar, Patrick P., Patel, Hitesh K., Bhagwati, Shripad S. (2009). “Identification dihydrochloride (AC220), a potent selective and uniquely effective FMS-like tyrosine kinase 3 (FLT3) inhibitor,” Journal of Medicinal Products Chemistry 52 (23). 7808-7816

Related posts Fostamatinib, Sick inhibitor shows promise in the treatment of B-cell malignancies and autoimmune diseases

Other-generation BCR-ABL kinase inhibitors for the treatment of CML, imatinib resistance in front of Quizartinib FLT3 inhibitor, shows promise for the treatment of acute myeloid leukemia

Imatinib – a “magic bullet “for treating chronic myelogenous leukemia

INTRODUCTION Chronic myelogenous leukemia (CML) is a myeloproliferative hematologic cancer characterized by unregulated proliferation of white blood cells and bone marrow collection … Early development of the BCL-2 inhibitors relieve painful symptoms of progressive lymphoma

Introduction Lymphoma is the most common hematologic malignancy, or cancer of the blood in the United States accounts for approximately 55% of tumors in and around the … Fostamatinib, Sick inhibitor shows promise in the treatment of B-cell malignancies and autoimmune diseases

INTRODUCTION Rheumatoid arthritis (RA) is a disabling and painful condition that affects about 1% of the world’s population. Onset usually occurs between the …

Article by Sanjeev

Here I describe the most common causes of cancer, Brian. What if you know the reasons early on, you can take the necessary precautions to stay far away from brain cancer.

1, the Gene Causes brain cancer: a gene normally found in chromosome 14 can cause cancer in the brain, which is the most common type of malignant brain cancer. Recently, scientists at the Stanford University School of Medicine, agreed that the deletion of genes, promoting tumor growth and increase resistance to therapy. This is often one of the four cases of brain cancer.

2, the main cause of Heredity: The risk of developing brain cancer is known to increase when a person has a family history of cancer. Cancer of the brain often occurs with the same family, so genetics may be the reason.

3 abnormal cells Mutation: Primary brain tumors begin when normal cells during DNA mutations occur. The mutation may allow cell growth and division of higher interest rates, and to continue to live as healthy cells die. As a result, the mass of abnormal cells form a tumor arises.

4 Un-controlled cell growth most often caused by a brain tumor Brain (Brain Cancer): We have a lot of different brain cells, and each with a different function. If any of these cases within the brain cells begin to grow uncontrollably, because it will definitely cause cancer.

5 Benign brain tumors are not cancer, but malignant tumors can be easily Malignancies: a brain tumor may or may not be malignant. If the tumor is benign in its place where it starts, but it can grow very large, and the pressure in key areas. In cases of malignant brain tumors, which have shown the ability to spread and cause cancer ..

6 Cancers that begin in other locations of the body that spreads to the brain cancer can develop in the brain (primary malignancy), or the spread of the tumor can be developed in the past affects the body. Is there any other body part of all kinds of cancer, and it is a great way to spread occurring cancers in the brain of an infected body part. This is the secondary (metastatic) brain tumor. . Breast cancer, lung, skin or blood cells (leukemia or lymphoma) can also spread (metastasize) to the brain

Article Source: http://EzineArticles.com/6710584

Article

terra Valley Association of leukemia

Finding help can be customized nutrition therapy for persons, experts say

Terra Alliance News: Steven Reinberg HealthDay Reporter. Genetic variations appear to influence how children care lymphoblastic leukemia, researchers report.

While 80 percent of children who suffer from blood and bone marrow cancer are cured, some children do not respond to treatment. Now scientists think they know why.

“For the first time we used the genome-wide strategies to listen to more than 500,000 DNA differences to find common inherited genetic variations called SNPs or single nucleotide polymorphisms, that predicted response to chemotherapy,” said researcher Mary V. Relling, who chairs the pharmaceutical department of St. Jude Children’s Research Hospital in Memphis, Tenn.

much emphasis on research why chemotherapy works better for some people than others have focused on differences in the leukemia cells themselves Relling noted.

“Our results show that the DNA patients inherit from their parents also explains why some patients respond to chemotherapy better than others,” he said. “We also found some interesting genes that were previously evaluated and may provide new targets for new drug development.”

report has been published on 28 January issue of the Journal of the American Medical Association. Investigation, the team studied genetic variations Relling 487 children lymphoblastic leukemia. Their goal was to find evidence of disease that persisted after treatment.

The researchers found 102 SNPs associated with minimal disease. “A large part of the gene variants were associated with blood levels of chemotherapy and leukemia cells, some of which were related to leukemia cell biology,” Relling said

Just as many, 21, was also included. blood-related relapse, and the performance of antileukemic drugs. A total of 61.7 percent of the SNP of early response, relapse risk or the performance of antileukemic drugs, the researchers found.

“Some of the genetic variation is likely to cause differences among patients, how quickly your body get rid of chemotherapy, and some of the differences can penetrate leukemia cells and affect the inherent sensitivity of leukemia cells to chemotherapy,” Relling said.Knowing genetics of patients and know the genetics of their tumors are so important in designing effective treatment, he explained.

“When modern genomics is used to try to personalize cancer treatment regimen, we must consider the genetic variation that each patient has inherited, in addition to the genetic variation that is unique to cancer cells,” Relling said. “It is necessary to continue to do so many genomic studies in cancer patients as possible in order to apply these results in the future.”

Dr. Barton Kamen, chief medical officer of Leukemia and Lymphoma Society, noted that nearly 20 percent of children treated for lymphoblastic leukemia suffer cognitive effects of chemotherapy. “The problem is that a high cure rate of lymphoblastic leukemia still has a price,” Kamen said. But knowing the genetic makeup of humans and their diseases, he said, could make possible the treatment less toxic by using lower doses for a shorter period of time.

In addition to knowing the genetic makeup of children lymphoblastic leukemia “might indicate the reasons for treatment, so that we can do something better 20 percent of children who are doomed to fail,” Kamen said.

More informationThe U. S. National Cancer Institute has more leukemia.

Terramet Alliance is a nonprofit organization in the fight against leukemia helps children with cancer and their families. Our goal is to ensure that children are fighting cancer know that they are not alone. For more information, please visit http://www.terramedalliance.org. E-mail contact@terramedalliance.org

Article by Adam

Franchise

Cancer is a disease in which certain cells in the body goes out of control and begin to multiply themselves. It is the uncontrolled growth of the tumor, and eventually, if unchecked, will interfere with the vital organ or organs and cause death.

This is not infection (even in some cases it may be caused by viral infections), but the outcome, most likely an inherited weakness of the genetic makeup, bad living habits and environments. Unhealthy diet, smoking, stress and long-term industrial pollution, for example, whether known or are highly likely to be, or the main contribution of risk factors for cancer.

the human body contains a total of not more than 200 different types of cells, which means that there are more than 200 different types of cancer. Abnormal growth, called a tumor or tumor (neo simply means “new”, and the plasma is “format”). The resulting disease is known neoplastic disease.

If a tumor or growth is purely local, and non-invasive it is described as benign. Good growth is not common, it is less harmful. Examples include moles, cysts and polyps. Growth, which can not be contained, and continue to spread unchecked has been known as a malignant growth. It is a cancer

Medical conditions related to the various Cali, how they grow in the body.

Carcinoma of skin cancer, including outside the body cavity and the inside lining (epithelium). This is by far the most common cancers including breast, lung, colon, prostate and skin. The most serious form of skin cancer, melanoma.

Sarcoma is a cancer of the bone, tendons, and muscles.

Lymphoma is a cancer of the glands (or nodes), or other parts of the lymphatic system

Leukemia is a cancer of the blood.

Cancer is different from country to country and from region to region. Some cancers are more interaction with Western countries such as North America and Europe than in Eastern countries, like Japan, or the so-called developing countries like Africa. Japan, for example, there are many more cases of gastric cancer in the West and Africa, liver cancer is much more prevalent than elsewhere. Overall, they found the ten most common cancers worldwide are lung, stomach, chest, lower abdomen, cervix, mouth, lymphatic system, liver, neck and prostate. None of the methods described provide treatment for cancer, but they can alleviate symptoms and support the immune system.

article by niz

What is cancer

There are quite a few signs of malignant tumors – Burkitt’s lymphoma and retinoblastoma and the thymoma and ovarian cancer, Low malignant potential tumors and lung cancer and head and neck cancer – just to list a few examples. But all of these tumors are a few things in common.

Loss of Control

Every cell in the body, such as adrenocorticotropic hormone, and prostacyclin without affecting the outside of cells and some other chemicals in cells. They relate to chemical control measures in the cell. They convey the cells grow and how much, when and how to be idle to communicate with other cells.

check for cancer cells is turned off. They do their thing without limitation. They are always active at the highest level. These malignant cells to lose control of their interaction with surrounding cells, and then to mobilize and move to other parts of the body.

Changes in DNA

All malignacies has lost control, because the cell DNA is damaged. DNA is the chemical programming of the cell, which determines all of its activities. That DNA is damaged by being broken, nuclear radiation or chemicals. DNA begins to act out of control. Virus has also been shown to cause DNA damage that leads to cancer.

Damaged DNA can also be sent to your child. The fact that DNA can provide a malignant tumor if it is the trigger to cell contacts, or even damage DNA.

Immortal Cells

Your body cells normally live only for a certain time and then die (with some exceptions). They will then be replaced by healthy new cells. Cancer cells usually do not die. Even if they are very unusual, they will only grow. When these cells make tumors, and live in delusion, that you can fix something that is not perfect. That’s why you married a man who was dying of cancer. Need does not love you. And now that your husband is dead, you’re looking for a charity. That’s why you go out with me. I’m twice your age, I’m not great, I’m not charming, I’m not even nice. What I have is what you need. I am hurt. Of Cancer, Dr.

All of these forms of cancer can be divided into five common types. They are central nervous system tumors, leukemia, carcinoma, lymphoma and myeloma, and Sarcoma

Central nervous system tumors -. These are tumors of the brain and spinal cord begin. Leukemia – these cancers start in tissues that produce blood – such as bone marrow – and then release the blood cells. Carcinoma – a cancer that begins in tissues or the skin, internal organs. Sarcoma – sarcomas are cancers that begin connective tissue. Connective tissue is the tissue between the organs and other structures. Include things such as fat tissue, bone, muscle, blood vessels and cartilage. Lymphoma and myeloma – are cancers from starting cells, which normally protects the body – the immune system.

Now you know what cancer is, you can learn how to prevent or, where appropriate, how to treat it.